Daniel S Baker

US Patent:

6875757, Apr 5, 2005

Filed:

Mar 19, 2001

Appl. No.:

09/811838

Inventors:

Duane D. Miller - Germantown TN, US
Gabor Tigyi - Memphis TN, US
James T. Dalton - Columbus OH, US
Vineet M. Sardar - Memphis TN, US
Don B. Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel L. Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David J. Fischer - Cordova TN, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US

Assignee:

University of Tennessee Research Foundation - Knoxville TN

International Classification:

A61K031/661
C07F009/06

US Classification:

514119, 558170

Abstract:

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

US Patent:

8022239, Sep 20, 2011

Filed:

Oct 2, 2009

Appl. No.:

12/572921

Inventors:

Daniel Lee Baker - Memphis TN, US
Louis Edward Montedonico - Memphis TN, US

Assignee:

The University of Memphis Research Foundation - Memphis TN

International Classification:

C07F 9/147

US Classification:

558210, 558 89, 558206

Abstract:

A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C-Cphosphodiesters and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds are non-cytotoxic, and can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of producing such novel compounds are encompassed within this invention as well as methods of inactivating autotaxin to certain degrees therewith.

US Patent:

8268891, Sep 18, 2012

Filed:

Nov 13, 2008

Appl. No.:

12/270840

Inventors:

Daniel Lee Baker - Memphis TN, US

Assignee:

University of Memphis Research Foundation - Memphis TN

International Classification:

A61K 31/17
A61K 31/19
A61K 31/496

US Classification:

514580, 514279, 514284, 514339, 514354, 514585, 514656, 514755

Abstract:

Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.

US Patent:

8343934, Jan 1, 2013

Filed:

Jun 30, 2010

Appl. No.:

12/828053

Inventors:

Daniel Lee Baker - Memphis TN, US
Elton Jeffrey North - Memphis TN, US

Assignee:

University of Memphis - Memphis TN

International Classification:

A61K 31/655
C07C 309/52
C07C 245/10

US Classification:

514 219, 514150, 514576, 514577

Abstract:

Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.

US Patent:

8497371, Jul 30, 2013

Filed:

Oct 26, 2010

Appl. No.:

12/912604

Inventors:

Daniel Lee Baker - Memphis TN, US
Adrienne Hoeglund - Collierville TN, US

Assignee:

University of Memphis Research Foundation - Memphis TN

International Classification:

C07D 471/04

US Classification:

544279

Abstract:

Novel and optimized classes of pipemidic acid derivative compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes of compounds exhibit exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.

US Patent:

20030130237, Jul 10, 2003

Filed:

Sep 18, 2001

Appl. No.:

09/953686

Inventors:

Duane Miller - Germantown TN, US
Gabor Tigyi - Memphis TN, US
James Dalton - Columbus OH, US
Vineet Sardar - Cordova TN, US
Don Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David Fischer - Cordova TN, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US

International Classification:

A61K031/663
A61K031/66

US Classification:

514/102000, 514/114000

Abstract:

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

US Patent:

20040204383, Oct 14, 2004

Filed:

Apr 9, 2004

Appl. No.:

10/821739

Inventors:

Gabor Tigyi - Memphis TN, US
Daniel Baker - Memphis TN, US
Chunxiang Zhang - Memphis TN, US

International Classification:

A61K031/739

US Classification:

514/054000

Abstract:

The phospholipid growth factor lysophosphatidic acids (LPAs) containing unsaturated fatty acids (18:1, 18:2 and 20:4) and fatty alcohols containing hydrocarbon chains with more than 4 carbons were capable of inducing a rapid formation of neointima, an initial step in the development of atherosclerotic plaque. LPAs with saturated fatty acids did not induce neointima formation. A Peroxisome Proliferator-Activated Receptors gamma (PPAR)-specific agonist Rosiglitasone also induced a profound formation of neointima. GW9662, a selective and irreversible antagonist of PPAR, abolished LPA- and Rosiglitazone-induced neointima formation, indicating that LPA-induced neointima formation requires the activation of PPAR. These data suggest that LPA analogs that bind to but do not activate downstream signaling of PPAR or antagonists of PPAR that inhibit PPAR signaling would be useful in the prevention and/or treatment of neointima formation and atherosclerosis.

US Patent:

20050261252, Nov 24, 2005

Filed:

Feb 28, 2005

Appl. No.:

11/067884

Inventors:

Duane Miller - Germantown TN, US
Gabor Tigyi - Memphis TN, US
James Dalton - Columbus OH, US
Vineet Sardar - Cordova TN, US
Don Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David Fischer - Plymouth MA, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US

International Classification:

A61K031/675
A61K031/663
C07F009/28

US Classification:

514091000, 514102000, 548112000, 558158000

Abstract:

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

Address:

5664 Bentgrass Run Dr, Charlotte, NC 28269

VIN:

5Y2SL65817Z435097

Make:

PONTIAC

Model:

VIBE

Year:

2007